Thiopurine methyltransferase activity in the inflammatory bowel disease. A study on 7046 Spanish patients;Actividad de la tiopurina metiltransferasa en la enfermedad inflamatoria intestinal. Un estudio en 7.046 pacientes españoles

Medicina Clinica

Volumn 125, Issue 8, 2005, Pages 281-285

  Gisbert, Javier P ^a,e   Gomollón, Fernando ^b   Cara, Carlos ^c   Luna, Marta ^a   González Lama, Yago ^a   Pajares, José María ^a   Maté, José ^a   Guijarro, Luis G ^d  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^d UNIVERSITY OF ALCALÁ   (Spain)

^e Playa de Mojacar   (Spain)

Author keywords

6 Mercaptopurine; Azathioprine; Crohn's disease; Inflammatory bowel disease; Thiopurine methyltransferase; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; MESALAZINE; STEROID; THIOPURINE METHYLTRANSFERASE;

ADULT; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RADIOASSAY; SPAIN; STATISTICAL ANALYSIS; ULCERATIVE COLITIS;

EID: 26844510445     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13078420     Document Type: Article

References (33)

1. Gisbert JP, Gomollón F, Maté J, Pajares JM. Preguntas y respuestas sobre el papel de la azatioprina y la 6-mercaptopurina en el tratamiento de la enfermedad inflamatoria intestinal. Gastroenterol Hepatol. 2002;25:401-15.
2. Tidd DM, Paterson AR. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res. 1974;34:738-46.
3. Gisbert JP, Gomollón F, Maté J, Pajares JM. Terapia individualizada con azatioprina o 6-mercaptopurina mediante monitorizació n de la actividad de la tiopurina metiltransferasa (TPMT). Rev Clin Esp. 2002;202:555-62.
4. Lennard L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol. 1999;47:131-43.
5. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-62.
6. Menor C, Fueyo J, Escribano O, Pina MJ, Redondo P, Cara C, et al. Thiopurine methyltransferase activity in a Spanish population sample: decrease of enzymatic activity in multiple sclerosis patients. Mult Scler. 2002;8:243-8.
7. Decaux G, Horsmans Y, Houssiau F, Desager JP. High 6-thioguanine nucleotide levels and low thiopurine methyltransferase activity in patients with lupus erythematosus treated with azathioprine. Am J Ther. 2001;8:147-50.
8. Gisbert JP, Luna M, Maté J, González-Guijarro L, Cara C, Pajares JM. Actividad de la tiopurina metiltransferasa y mielotoxicidad debida a azatioprina y 6-mercaptopurina en pacientes con enfermedad inflamatoria del intestino. Med Clin (Barc). 2003;121:1-5.
9. Menor C, Fueyo JA, Escribano O, Cara C, Fernández-Moreno MD, Román ID, et al. Determination of thiopurine methyltransferase activity in human erythrocytes by high-performance liquid chromatography: comparison with the radiochemical method. Ther Drug Monit. 2001;23: 536-41.
10. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol. 1995;131:193-7.
11. Lowenthal A, Meyerstein N, Ben-Zvi Z. Thiopurine methyltransferase activity in the Jewish population of Israel. Eur J Clin Pharmacol. 2001;57: 43-6.
12. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, Vinner E, Marez D, Lo Guidice JM, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol. 1998;125:879-87.
13. Park-Hah JO, Klemetsdal B, Lysaa R, Choi KH, Aarbakke J. Thiopurine methyltransferase activity in a Korean population sample of children. Clin Pharmacol Ther. 1996;60:68-74.
14. Kroplin T, Weyer N, Gutsche S, Iven H. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol. 1998;54: 265-71.
15. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics. 1992;2:148-59.
16. Corominas H, Doménech M, González D, Díaz C, Roca M, García-González MA, et al. Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls. Am J Gastroenterol. 2000;95: 2313-7.
17. Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther. 2002:16:389-98.
18. Mircheva J, Legendre C, Soria-Royer C, Thervet E, Beaune P, Kreis H. Monitoring of azathioprine-induced immunosuppression with thiopurine methyltransferase activity in kidney transplant recipients. Transplantation. 1995;60:639-42.
19. Thervet E, Anglicheau D, Toledano N, Houllier AM, Noel LH, Kreis H, et al. Long-term results of TMPT activity monitoring in azathioprine-treated renal allograft recipients. J Am Soc Nephrol. 2001;12:170-6.
20. Weyer N, Kroplin T, Fricke L, Iven H. Human thiopurine S-methyltransferase activity in uremia and after renal transplantation. Eur J Clin Pharmacol. 2001;57:129-36.
21. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation. 1992;53:1051-6.
22. Schutz E, Gummert J, Mohr FW, Armstrong VW, Oellerich M. Azathioprine myelotoxicity related to elevated 6-thioguanine nucleotides in heart transplantation. Transplant Proc. 1995;27:1298-300.
23. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther. 1987;41:18-25.
24. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990;336:225-9.
25. McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood. 1995;85:1897-902.
26. Keuzenkamp-Jansen CW, Leegwater PA, De Abreu RA, Lambooy MA, Bokkerink JP, Trijbels JM. Thiopurine methyltransferase: a review and a clinical pilot study. J Chromatogr B Biomed Appl. 1996;678:15-22.
27. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol. 1995;39:456-9.
28. Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilboum RM, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther. 1997;62:464-75.
29. Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001;49: 656-64.
30. Lowry PW, Franklin CL, Weaver AL, Gennett Pike M, Mays DC, Tremaine WJ, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut. 2001;49:665-70.
31. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology. 1999; 116:1505-6.
32. Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol. 2001;13:1297-301.
33. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904-15.